Search

Displaying results 611 - 620 of 9682 in total
  1. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. … [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.

  2. Drug

    CA-170

    go.drugbank.com/drugs/DB15772
    Investigational

    CA-170 is a selective, small molecule inhibitor of PD-L1.

  3. Drug

    Eprodisate

    go.drugbank.com/drugs/DB06405
    Investigational

    Eprodisate slows the decline of renal function in AA amyloidosis.

  4. Drug

    Lorajmine

    go.drugbank.com/drugs/DB13651
    Experimental

    Categories: Antiarrhythmics, Class Ia
  5. Drug

    Zuclopenthixol

    go.drugbank.com/drugs/DB01624
    ApprovedInvestigational

    Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. … This drug is a liquid. This compound belongs to the thioxanthenes.

  6. Drug

    Hydroquinidine

    go.drugbank.com/drugs/DB15300
    Investigational

    Hydroquinidine is under investigation in clinical trial NCT00927732 (Hydroquinidine Versus Placebo in Patients With Brugada Syndrome).

    Categories: Antiarrhythmics, Class Ia
  7. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  8. Drug

    Prolgolimab

    go.drugbank.com/drugs/DB16740
    Investigational

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  9. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV. … In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend ledipasvir as a first line

  10. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    [L10253] Elbasvir and [grazoprevir] are used with or without [ribavirin] with the intent to cure, or achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% … Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly.